Evidence map›Paper›PMID 36186622›Full record

ArticleNMC case report journal2022

Gliosarcoma with Systemic Metastasis Showing Favorable Response to Ifosfamide, Carboplatin, and Etoposide Chemotherapy: An Autopsy Case Report.

Yuki Nakagaki, Keitaro Kai, Yoshihiro Komohara, Tatsuya Takezaki, Junichiro Kuroda, Naoki Shinojima, Mari Shimomura, Fumi Kawakami, Yoshiki Mikami, Akitake Mukasa

Abstract readCase Reports
In one paragraph

Article in NMC case report journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuki NakagakiDepartment of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Keitaro KaiDepartment of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Yoshihiro KomoharaDepartment of Cell Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Tatsuya TakezakiDepartment of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Junichiro KurodaDepartment of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Naoki ShinojimaDepartment of Diagnostic Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Mari ShimomuraDepartment of Diagnostic Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Fumi KawakamiDepartment of Diagnostic Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Yoshiki MikamiDepartment of Diagnostic Pathology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Akitake MukasaDepartment of Neurosurgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliosarcoma is a rare malignant neoplasm. It accounts for approximately 2% of all glioblastomas. To date, there is no established treatment method for gliosarcoma, and a variety of therapies, such as surgical resection, radiotherapy, and chemotherapy, are typically employed. Here, we describe a patient with gliosarcoma who, despite multiple tumor metastases throughout the body, including the lungs and lymph nodes, achieved a relatively long survival due to salvage therapy with local irradiation and remarkably effective chemotherapy with low-dose ifosfamide, carboplatin, and etoposide therapy. When the patient died, we performed autopsy and confirmed the nature of the primary and metastatic tumor cells that had spread throughout the patient's body. Clinical and systemic histological studies also suggested the possibility of re-metastasis to the brain from systemic metastatic foci. Gliosarcoma appears to have characteristics similar to sarcoma as well as a higher risk of systemic metastasis. Therefore, a careful follow-up is necessary in such patients.

Indexed as

extracranial metastasisgliosarcomaICE chemotherapy

Identifiers

PMID36186622
PMCPMC9484818

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.